BERKELEY HEIGHTS, N.J., Jan. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company) reviewed its 2017 achievements and provided an outline of the Company's key business objectives for 2018. These will be highlighted at the Company's presentation during the Biotech Showcase™ 2018 Conference at 2:30 p.m. PST, Tuesday, January 9, 2018, at the Hilton San Francisco Union Square in San Francisco.
“During 2017, we selected a recommended Phase 2 dose (RP2D), for our CYC065 CDK inhibitor, and advanced our clinical programs in selected patient populations relevant to the drugs’ mechanism,” said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. “In an ongoing, Phase 1 study, CYC065 demonstrated durable target engagement and biomarker suppression at well tolerated doses in 11 out of 13 patients treated at the RP2D. Initial anticancer activity was observed in five patients. In 2018, we plan to initiate a translational clinical study to evaluate CYC065 in combination with venetoclax in chronic lymphocytic leukemia, or CLL; design clinical studies for CYC065 alone and with standard of care in solid tumors, including certain pediatric cancers. Data from the Phase 3 SEAMLESS study of sapacitabine were recently presented at the American Society of Hematology, or ASH, Annual Meeting. The presentation included additional data emerging from a comprehensive analysis of prespecified subgroups, e.g. low peripheral white blood cell count, which will form the basis of the Company’s consultations with regulatory authorities. Following our July offering, we project cash resources to fund currently planned programs through the end of 2019. We look forward to reporting our progress in 2018.”
Transcriptional Regulation Program: CYC065 CDK inhibitor
DNA Damage Response (DDR) Program
SEAMLESS Phase 3 Study
PLK1 Inhibitor; CYC140
2018 Key Upcoming Business Objectives
For the live and archived webcast of the Company's presentation at the Biotech Showcase™ 2018 San Francisco conference, please visit the Corporate Presentations page on the Cyclacel website at www.cyclacel.com. The webcast will be archived for 90 days and the audio replay for seven days.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.Contacts Company: Paul McBarron, (908) 517-7330, email@example.com Investor Relations: Russo Partners LLC, Alexander Fudukidis, (646) 942-5632, firstname.lastname@example.org
© Copyright 2018 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are registered trademarks.